ONCOLOGY-NEW YORK

Scope & Guideline

Shaping the Future of Cancer Treatment Through Knowledge.

Introduction

Welcome to your portal for understanding ONCOLOGY-NEW YORK, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0890-9091
PublisherUBM MEDICA
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationONCOLOGY-NY / Oncology-NY
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854

Aims and Scopes

The journal 'ONCOLOGY-NEW YORK' focuses on advancing knowledge and practice in the field of oncology by publishing peer-reviewed articles that cover a broad spectrum of cancer-related topics. Its aims and scopes reflect both clinical and research aspects of oncology, emphasizing innovative treatments, patient care strategies, and the integration of new technologies in cancer management.
  1. Clinical Trials and New Treatments:
    The journal extensively covers findings from clinical trials, particularly those that introduce novel therapies or treatment combinations for various cancers, including hematological malignancies and solid tumors.
  2. Multidisciplinary Approaches:
    A strong emphasis is placed on the importance of a multidisciplinary approach in oncology, integrating insights from surgery, medical oncology, radiation therapy, and supportive care to enhance patient outcomes.
  3. Emerging Technologies and Innovations:
    The journal highlights advancements in technology, such as artificial intelligence and liquid biopsy, that have the potential to transform cancer diagnosis and treatment.
  4. Patient-Centric Care and Quality of Life:
    Research focusing on patient experiences, psychosocial aspects of cancer treatment, and strategies for improving quality of life for cancer patients is a consistent theme.
  5. Health Equity and Access to Care:
    The journal addresses disparities in cancer care, advocating for equitable access to treatment and highlighting the impact of socioeconomic factors on cancer outcomes.
Recent publications in 'ONCOLOGY-NEW YORK' indicate emerging trends that reflect the evolving landscape of oncology research and practice. These trends highlight new areas of focus that are gaining traction among researchers and clinicians alike.
  1. Immunotherapy and Targeted Therapies:
    There is a significant increase in research surrounding immunotherapies and targeted treatments, particularly in hematologic malignancies and solid tumors, showcasing their transformative potential in cancer care.
  2. Artificial Intelligence in Oncology:
    The integration of artificial intelligence to improve treatment outcomes and patient management strategies is a rapidly growing theme, reflecting the broader trend of utilizing technology to enhance healthcare delivery.
  3. Patient-Reported Outcomes and Quality of Life:
    An increasing emphasis on patient-reported outcomes and the quality of life of cancer patients is evident, highlighting the importance of holistic care and patient-centered approaches in oncology.
  4. Genomic and Biomarker Research:
    The exploration of genomic profiling and biomarkers for predicting treatment responses and personalizing therapy is trending, indicating a move towards precision medicine in oncology.
  5. Health Equity and Disparities in Cancer Care:
    Discussions around health equity and addressing disparities in cancer treatment access are becoming more prominent, reflecting growing awareness and advocacy for equitable healthcare solutions.

Declining or Waning

While 'ONCOLOGY-NEW YORK' continues to evolve, certain themes have shown a decline in prominence in recent publications. This may reflect shifting priorities within the oncology community or changes in research funding and interest.
  1. Traditional Chemotherapy Protocols:
    As newer targeted therapies and immunotherapies gain traction, traditional chemotherapy protocols are being discussed less frequently, indicating a shift towards more personalized treatment approaches.
  2. Historical Perspectives on Cancer Treatment:
    There appears to be a waning interest in retrospective analyses of older treatment regimens, as the focus shifts towards innovative and cutting-edge therapies.
  3. General Oncological Guidelines Without Specificity:
    Broad discussions around general oncology guidelines are becoming less common, replaced by more specific studies and recommendations tailored to individual cancer types or patient populations.

Similar Journals

BREAST CANCER RESEARCH AND TREATMENT

Fostering Collaboration for Better Outcomes
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Nature Reviews Clinical Oncology

Pioneering Insights for Tomorrow's Treatments
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

International Journal of Clinical Oncology

Elevating Standards in Cancer Treatment and Research
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

ESMO Open

Transforming insights into impactful cancer solutions.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

Oncology Research and Treatment

Elevating cancer research to new heights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

JNCI Cancer Spectrum

Transforming cancer insights into impactful discoveries.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 6 issues/year

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

Discover Oncology

Pioneering multidisciplinary research in oncology and beyond.
Publisher: SPRINGERISSN: Frequency: 1 issue/year

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

Cancer Management and Research

Pioneering new paths in cancer management and research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

ONCOLOGY REPORTS

Championing Innovative Insights in Oncology
Publisher: SPANDIDOS PUBL LTDISSN: 1021-335XFrequency: 12 issues/year

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

World Journal of Clinical Oncology

Empowering Oncology with Cutting-Edge Insights
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.